Context Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Context Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-121,797	Closed	-$1.21M	–	581
2021 Q3	$1.21M	Sell	121,797 -3,200	-3%	-$31.8K	0.12%	202
2021 Q2	$1.25M	Buy	124,997 +24,997	+25%	+$251K	0.12%	203
2021 Q1	$996K	Buy	+100,000	New	+$1.03M	0.1%	215

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

FCOMV

Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

JCM

JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Context Capital Management's PRDS Position: Q4 2021 in Review

Context Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q4 2021, closing a stake of 121,797 shares — an estimated $1.21M sold.

Context Capital Management first reported a position in PRDS in Q1 2021 and held it in 3 quarters. The position peaked at $1.25M in Q2 2021. 41 funds tracked by Wall St. Rank hold PRDS as of Q4 2021.

Context Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Context Capital Management sold 121,797 Pardes Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $1.21M.
Context Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
Context Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $1.25M in Q2 2021.
41 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q4 2021.

Based on Context Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.